Case Reports in Medicine References [1] S. K. Klein, E. J. Slim, M. D. de Kruif, T. T. Keller, H. ten Cate, E. C. M. van Gorp, and D. P. M. Brandjes, “Is chronic HIV infection associated with venous thrombotic disease? A sytematic review,” Netherlands Journal of Medicine, vol. 63, no. 4, pp. 129–136, 2005. [2] V. Rickerts, H. Brodt, S. Staszewski, and W. Stille, “Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study,” European Journal of Medical Research, vol. 5, no. 8, pp. 329–333, 2000. [3] J. D. Lundgren, “Combination antiretroviral therapy and the risk of myocardial infarction. The data collection on adverse events of anti-HIV drugs (DAD) Study Group,” New England Journal of Medicine, vol. 349, no. 21, pp. 1993–2003, 2003. [4] C. S. Restrepo, L. Diethelm, J. A. Lemos, E. Vela´squez, T. A. Ovella, S. Martinez, J. Carrillo, and D. F. Lemos, “Cardio- vascular complications of human immunodeﬁciency virus infection,” Radiographics, vol. 26, no. 1, pp. 213–231, 2006. [5] A. A. Saber, A. Aboolian, R. D. LaRaja, H. Baron, and K. Hanna, “HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement,” American Surgeon, vol. 67, no. 7, pp. 645–647, 2001. [6] E. J. Bloom, D. I. Abrams, and G. Rodgers, “Lupus anticoagu- lant in the acquired immunodeﬁciency syndrome,” Journal of the American Medical Association, vol. 256, no. 4, pp. 491–493, 1986. [7] K. Koppel, G. Bratt, S. Schulman, H. Bylund, and E. Sand- stro¨m, “Hypoﬁbrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 29, no. 5, pp. 441–449, 2002. [8] A. Majluf-Cruz, M. Silva-Estrada, R. Sa´nchez-Barboza, G. Montiel-Manzano, S. Trevin˜o-Pe´rez, M. Santoscoy-Go´ mez, A. Ruiz De Cha´vez-Ochoa, N. Corona-De La Pen˜a, and L. Nieto- Cisneros, “Venous thrombosis among patients with AIDS,” Clinical and Applied Thrombosis/Hemostasis, vol. 10, no. 1, pp. 19–25, 2004. [9] P. Toulon, M. Lamine, I. Ledjev, T. Guez, M. E. Holleman, D. Sereni, and D. Sicard, “Heparin cofactor II deﬁciency in patients infected with the human immunodeﬁciency virus,” Thrombosis and Haemostasis, vol. 70, no. 5, pp. 730–735, 1993. [10] L. Herstein and A. Cappacino, “Platelet functional and bound antibodies in AIDS-ARC patients with thrombocytopenia (Abstract),” Blood, vol. 70, no. 1, p. 118, 1987. [11] M. Witz, J. Lehmann, and Z. Korzets, “Acute brachial artery thrombosis as the initial manifestation of human immunode- ﬁciency virus infection,” American Journal of Hematology, vol. 64, no. 2, pp. 137–139, 2000. [12] M. C. Jacobson, B. J. Dezube, and D. M. Aboulaﬁa, “Throm- botic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series,” Clinical Infectious Diseases, vol. 39, no. 8, pp. 1214–1222, 2004. [13] P. D. Stein, A. Beemath, F. Matta, J. G. Weg, R. D. Yusen, C. A. Hales, R. D. Hull, K. V. Leeper Jr., H. D. Sostman, V. F. Tapson, J. D. Buckley, A. Gottschalk, L. R. Goodman, T. W. Wakeﬁed, and P. K. Woodard, “Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II,” American Journal of Medicine, vol. 120, no. 10, pp. 871–879, 2007. [14] J. H. Stein, M. A. Klein, J. L. Bellehumeur, P. E. McBride, D. A. Wiebe, J. D. Otvos, and J. M. Sosman, “Use of human immunodeﬁciency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunc- tion,” Circulation, vol. 104, no. 3, pp. 257–262, 2001. 3 [15] M. W. Saif, R. Bona, and B. Greenberg, “Aids and thrombosis: retrospective study of 131 HIV-infected patients,” AIDS Patient Care and STDs, vol. 15, no. 6, pp. 311–320, 2001.